期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 23, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/ijms23116059
关键词
micro-immunotherapy; MIM-seq; macrophages; immunomodulation; potential anti-tumor agent; colorectal cancer; 3D tumor spheroids
资金
- Labo'Life France
This study evaluated the immunomodulatory effects of MIM-seq on human macrophages and its potential anti-tumor properties against colorectal cancer (CRC). The results showed that MIM-seq inhibited pro-inflammatory cytokine secretion and displayed anti-proliferative effects on tumor cells. When combined with other anti-cancer agents, MIM-seq further reduced tumor growth, suggesting its potential as an adjuvant therapy for CRC patients.
In this study, the immunomodulatory effects of a sequential micro-immunotherapy medicine, referred as MIM-seq, were appraised in human primary M1 and M2 macrophages, in which the secretion of pro-inflammatory cytokines, such as interleukin (IL)-1 beta, IL-6, IL-12, IL-23, and tumor necrosis factor (TNF)-alpha, was inhibited. In addition, the potential anti-proliferative effects of MIM-seq on tumor cells was assessed in three models of colorectal cancer (CRC): an in vitro two-dimensions (2D) model of HCT-116 cells, an in vitro tri-dimensional (3D) model of spheroids, and an in vivo model of subcutaneous xenografted mice. In these models, MIM-seq displayed anti-proliferative effects when compared with the vehicle. In vivo, the tumor growth was slightly reduced in MIM-seq-treated animals. Moreover, MIM-seq could slightly reduce the growth of our spheroid models, especially under serum-deprivation. When MIM-seq was combined with two well-known anti-cancerogenic agents, either resveratrol or etoposide, MIM-seq could even further reduce the spheroid's volume, pointing up the need to further assess whether MIM-seq could be beneficial for CRC patients as an adjuvant therapy. Altogether, these data suggest that MIM-seq could have anti-tumor properties against CRC and an immunomodulatory effect towards the mediators of inflammation, whose systemic dysregulation is considered to be a poor prognosis for patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据